Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia

Phase 3

• Conditions: Schizophrenia
• Interventions: Drug: Placebo; Drug: Amantadine

• Registration Number: NCT00999505
• Lead Sponsor: Hospital de Clinicas de Porto Alegre

Brief Summary

Amantadine as add-on therapy to antipsychotics may improve schizophrenia positive, negative and cognitive symptoms.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-10-20
• Study First Submitted QC: 2009-10-20
• Study First Posted: 2009-10-21
• Study Start: 2010-05
• Status Verified: 2011-02
• Last Update Submitted: 2011-02-15
• Last Update Posted: 2011-02-16
• Primary Completion: 2011-09
• Study Completion: 2011-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Under antipsychotics with residual symptoms

Exclusion Criteria

• Pregnancy
• Lactation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo capsules twice a day
Amantadine	Amantadine	Amantadine 200mg twice a day

Primary Outcome Measures

Name	Time	Method
Scores in Brief Psychiatric Rating Scale	Baseline, 4 weeks, 8 weeks, 12 weeks

Trial Locations

Locations (1)

Hospital de Clinicas de Porto Alegre; 🇧🇷 Porto Alegre, RS, Brazil